I'm LongbridgeAI, I can summarize articles.The Week
Phillip Morris (PM) fell 7.47% this week to close at $184.09, while the S&P 500 lost 8.61%, meaning the stock outperformed the benchmark by about 1.14 percentage points. The week trended lower rather than gapping down once. Monday (16 Nov) opened at $200 and slid; Tuesday (17 Nov) and Wednesday (18 Nov) posted back-to-back declines; Thursday (19 Nov) and Friday (20 Nov) widened losses, with Friday’s intraday low of $183.53 sitting right at the weekly close.
Key Events
Coverage this week centred on the company’s valuation debate and a regulatory development in its next-generation products. On Thursday (19 Nov), subsidiary RBH urged consultation on Newfoundland and Labrador’s vape flavour ban, while other notes questioned what doubters may have overlooked. On Friday (20 Nov), one article asked whether PM is undervalued after its earnings beat and dividend rise. There was no major partnership or surprise earnings during the week.
Analyst Ratings
Of 18 covering institutions, 9 rate it buy, 3 rate it over, 5 rate it hold, and 1 has no opinion, with no sell or under ratings. Consensus rating is buy, and the consensus target is $212.6875, about 15.5% above the latest price. Targets range from $175 to $240, a fairly wide spread. The stock ranks first in its industry.
The Week Ahead
On Tuesday (24 Nov), a dense run of US macro data arrives: FHFA house prices, Case Shiller 20-city home price indices, consumer confidence, and the Richmond Fed composite index. Further out, Phillip Morris’ FY2026 annual results are scheduled for pre-market on 5 Feb 2027.
In Short
The stock pulled back this week, yet consensus rating remains buy and the consensus target sits about 15.5% above spot, revealing a gap between institutional pricing and market price. In the latest session, small-lot money was a net seller. The question now is whether next year’s earnings and regulatory progress can close that gap.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
